Toxic Injury to the Gastrointestinal Tract After Ipilimumab Therapy for Advanced Melanoma.

Ipilimumab, cytotoxic T-lymphocyte-associated protein 4-blocking antibody, is known to precipitate tissue-specific immune-related adverse events. The second most common site for immune-related adverse events is the gastrointestinal tract, with toxic injury resulting in diarrhea, colitis, and enterocolitis. In the present case, a woman who received ipilimumab 2 weeks prior was found to have severe, diffuse corticosteroid-refractory gastrointestinal tract toxic injury affecting the stomach, small bowel, and colon.